Welcome: Guest | Site Use Options | Register | Login |

Taligen Therapeutics Inc

Taligen Therapeutics Inc

Profile last edited on: 5/13/2019
245 First Street Suite 1100
Cambridge, MA 02142
  (617) 299-3200
  info@taligentherapeutics.com
  www.taligentherapeutics.com
Business Identifier: Compounds to treat inflammatory diseases
Public Profile:
In January 2011, Taligen Therapeutics Inc was acquired by Alexion Pharmaceuticals Inc. (another SBIR firm). With facilities also in Colorado, Taligen had been a biotechnology company at the forefront of one of the new frontiers of anti-inflammatory and autoimmune drug development, complement system regulation. Taligens lead technology was directed at inhibiting factor B, an essential component in the amplification of complement activation. Inhibition of factor B down-regulates complement activation, thereby dampening the inflammatory response.. Taligens second technology was able to target complement inhibitors specifically to sites where excessive complement activation is occurring, thereby controlling inflammation at a specific tissue site. Rapidly advancing multiple clinical candidates and building a deep product candidate pipeline, Taligens lead therapeutic candidates are recombinant fusion proteins and monoclonal antibodies focused on orphan diseases, age-related macular degeneration (AMD), and severe inflammatory diseases. Taligens therapeutics precisely and selectively target key pathways in the complement system, particularly the amplification loop, offering a unique way to interrupt disease processes at the right point. Based on local and targeted regulation of the undesirable effects of excessive amplification of the complement system, Taligens platform had been built upon recent discoveries that have shown that excessive activity of the complement amplification loop is central to the pathogenesis of a number of important diseases. The effort was to use the firm's proprietary technology and unique capabilities to develop novel therapeutics that precisely target sites of disease and intervene before over activity of the complement amplification loop initiates harmful inflammatory responses. With Taligens founders and scientific collaborators having made some of the groundbreaking discoveries relating to the genetic drivers and biological processes that lead to over activation and excessive amplification of the complement system in chronic, life-threatening diseases.

 Synopsis: Awardee Business Condition
Year Founded First SBIR Year Date of Last Award
Employee Range VC funded? IP Holdings
Revenue Range Private/Public Exchange/Symbol :

Unlock access

To unlock access to all SBIR-STTR company Profiles, a FREE site registration is required. Click here to register or login if you already have an account

Smart Office Options

SBIR firms in the news



WikiProfile

Is this YOUR Company?

Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached

Do you know about this Awardees?

Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Contact information

Innovation Development Institute, LLC

   45 Beach Bluff Avenue, Suite 300
     Swampscott,  MA 01907-1542

  Tel:  (781) 595-2920

  support@inknowvation.com